Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss
in postmenopausal women, but whether it reduces fracture risk in these women is not
known.